文献速递MDS 与骨髓增殖性肿瘤白血病

Hippo激酶缺失通过慢性固有免疫激活促进del(20q)血液肿瘤

Hippo kinase loss contributes to del(20q) hematologic malignancies through chronic innate immune activation.
PubMed 文献 · Blood · 2019-01-01

研究发现del(20q)常见缺失区内的STK4(编码Hippo激酶MST1)在MDS和MPN中表达低于单倍剂量不足水平。小鼠造血特异性基因失活可诱导脾肿大、血小板减少、巨核细胞发育异常及慢性粒细胞增多倾向,类似del(20q)患者表型。在JAK2-V617F模型中,杂合性Hippo激酶失活加速致死性骨髓纤维化发展,且与固有免疫相关促炎细胞因子产生协同增加,IRAK1/4抑制剂可挽救异常升高的IL-1β产生。

要点

  • STK4在MDS和MPN中表达下调至单倍剂量不足水平以下。
  • 小鼠Hippo激酶缺失重现del(20q)相关血液学表型。
  • JAK2-V617F与Hippo激酶失活协同加速骨髓纤维化。

核心结论

  • Hippo激酶MST1(STK4)在del(20q)相关血液肿瘤生物学中具有核心作用,并揭示MPN不良进展的新分子基础,可能通过IRAK1抑制进行靶向干预。

研究设计与样本

  • 研究通过评估患者基因表达、小鼠造血特异性基因失活及JAK2-V617F模型进行。

主要发现

  • 患者基因表达评估显示STK4在MDS和MPN中下调至单倍剂量不足水平以下。
  • 小鼠造血特异性Hippo激酶失活诱导脾肿大、血小板减少、巨核细胞发育异常和慢性粒细胞增多倾向,类似del(20q)患者表型。
  • JAK2-V617F模型中杂合性Hippo激酶失活加速致死性骨髓纤维化发展。
  • 骨髓纤维化转化与JAK2-V617F和Hippo激酶失活对固有免疫相关促炎细胞因子(包括IL-1β和IL-6)产生的协同效应相关。
  • MST1与IRAK1相互作用,shRNA介导的敲低足以增加人髓系细胞中IRAK1依赖的NF-κB固有免疫激活。

关键数值与推荐

  • 小分子IRAK1/4抑制剂治疗挽救了JAK2-V617F MPN模型中异常升高的IL-1β产生。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Heterozygous deletions within chromosome 20q, or del(20q), are frequent cytogenetic abnormalities detected in hematologic malignancies. To date, identification of genes in the del(20q) common deleted region that contribute to disease development have remained elusive. Through assessment of patient gene expression, we have identified STK4 (encoding Hippo kinase MST1) as a 20q gene that is downregulated below haploinsufficient amounts in myelodysplastic syndrome (MDS) and myeloproliferative neoplasm (MPN). Hematopoietic-specific gene inactivation in mice revealed Hippo kinase loss to induce splenomegaly, thrombocytopenia, megakaryocytic dysplasia, and a propensity for chronic granulocytosis; phenotypes that closely resemble those observed in patients harboring del(20q). In a JAK2-V617F model, heterozygous Hippo kinase inactivation led to accelerated development of lethal myelofibrosis, recapitulating adverse MPN disease progression and revealing a novel genetic interaction between these 2 molecular events. Quantitative serum protein profiling showed that myelofibrotic transformation in mice was associated with cooperative effects of JAK2-V617F and Hippo kinase inactivation on innate immune-associated proinflammatory cytokine production, including IL-1β and IL-6. Mechanistically, MST1 interacted with IRAK1, and shRNA-mediated knockdown was sufficient to increase IRAK1-dependent innate immune activation of NF-κB in human myeloid cells. Consistent with this, treatment with a small molecule IRAK1/4 inhibitor rescued the aberrantly elevated IL-1β production in the JAK2-V617F MPN model. This study identified Hippo kinase MST1 (STK4) as having a central role in the biology of del(20q)-associated hematologic malignancies and revealed a novel molecular basis of adverse MPN progression that may be therapeutically exploitable via IRAK1 inhibition.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Stoner SA, Yan M, Liu KTH, et al. Hippo kinase loss contributes to del(20q) hematologic malignancies through chronic innate immune activation. Blood. 2019. PMID: 31434702. doi:10.1182/blood.2019000170

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。